Truqap (Capivasertib): A New Hope for Certain Breast Cancers

Understanding Truqap (Capivasertib) for Advanced Breast Cancer Breast cancer remains a significant health concern for women worldwide, and advancements in treatment are crucial for improving outcomes. Truqap, with its active ingredient capivasertib, represents a new frontier in targeted therapy for specific types of advanced breast cancer. This blog post aims to provide a comprehensive overview of Truqap, its mechanism of action, who can benefit from it, potential side effects, dosage, and its place in the treatment landscape, tailored for an Indian audience seeking clear and practical information. What is Truqap (Capivasertib)? Truqap is a prescription medication approved for the treatment of certain types of advanced or metastatic breast cancer in adults. It is a targeted therapy, meaning it works by interfering with specific molecules involved in cancer cell growth and survival. Truqap is used in combination with another drug called fulvestrant (Faslodex). This combination therapy is specifically indicated for breast cancer that meets particular genetic criteria and has shown resistance to prior endocrine-based treatments. Who Can Benefit from Truqap? Truqap is not for all breast cancer patients. It is prescribed for adults with breast cancer that: Is locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). Is HER2-negative (human epidermal growth factor receptor 2-negative). Has an atypical gene alteration in PIK3CA, AKT1, or PTEN. These genetic mutations are found in some breast cancer cells and can drive cancer growth. Has worsened or returned within 12 months after completing treatment with at least one endocrine-based drug. Before starting Truqap, your doctor will conduct specific tests on your cancer cells to confirm the presence of these genetic alterations. This ensures that the treatment is appropriate and has the highest chance of being effective for your specific cancer type. How Does Truqap Work? Truqap is a type of drug known as an AKT inhibitor. The AKT enzyme plays a vital role in cell growth, survival, and metabolism. In certain breast cancers, particularly those with mutations in the PIK3CA, AKT1, or PTEN genes, the AKT enzyme becomes overactive. This overactivity can promote the uncontrolled growth and spread of cancer cells. By blocking the action of the AKT enzyme, Truqap helps to inhibit the growth and proliferation of these specific cancer cells. When used in combination with fulvestrant, it enhances the overall anti-cancer effect, providing a more robust treatment response for eligible patients. Dosage and Administration Truqap is administered as an oral tablet and is available in two strengths: 160 mg and 200 mg. The recommended dosage is 400 mg taken twice daily. The dosing schedule is typically administered over a 4-day cycle, followed by a 3-day break, and then the cycle repeats. This specific schedule is designed to maintain consistent drug levels in the body while managing potential side effects. Key points regarding dosage: Timing: It is best to take Truqap around the same time each day to maintain consistent drug levels. Separation: Doses should be separated by approximately 12 hours. Consult your doctor: Always follow your doctor's specific instructions regarding dosage and schedule. Do not adjust the dose or stop treatment without consulting your healthcare provider. Potential Side Effects of Truqap Like all medications, Truqap can cause side effects, ranging from mild to serious. It's important to be aware of these potential effects and to discuss them with your doctor. The likelihood and severity of side effects can depend on individual factors, including your overall health and other medications you may be taking. Common Mild Side Effects: Some common mild side effects reported with Truqap include: Gastrointestinal issues: Nausea, vomiting, diarrhea, and mouth sores (stomatitis). Skin reactions: Dry skin, rash, itching, and sometimes skin ulcers. Fatigue: Feeling tired or lacking energy. Changes in appetite: Loss of appetite or changes in taste. Other: Headache, dizziness, and changes in certain blood cell counts. Most mild side effects can be managed with supportive care and may resolve over time. Your doctor can offer advice on managing these symptoms. Serious Side Effects: While less common, Truqap can cause serious side effects that require immediate medical attention. These include: Low Blood Cell Counts: Decreased levels of lymphocytes, leukocytes, neutrophils, and platelets, which can increase the risk of infection and bleeding. Kidney Problems: Including sudden kidney injury, protein in the urine, and potentially kidney failure. High Blood Sugar: Severely elevated blood sugar levels, which can lead to a serious condition called diabetic ketoacidosis. Severe Diarrhea: Leading to dehydration. Severe Skin Reactions: Such as erythema multiforme, hand-foot syndrome, and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Allergic Reactions: Signs may include rash, itching, swelling, severe dizziness, or trouble breathing. If you experience any signs of serious side effects, contact your doctor immediately. If you believe you are experiencing a medical emergency, call your local emergency number (like 108 or 112 in India) or go to the nearest hospital emergency room. Drug Interactions Truqap can interact with other medications, potentially affecting how it works or increasing the risk of side effects. It is crucial to inform your doctor about all the medications, supplements, and herbal products you are currently taking. This includes over-the-counter drugs and any new medications you start during your treatment. When to Consult a Doctor It is essential to maintain regular contact with your healthcare team while undergoing Truqap treatment. You should consult your doctor: Before starting Truqap to confirm eligibility and discuss potential risks. If you experience any new

In summary, timely diagnosis, evidence-based treatment, and prevention-focused care improve long-term health outcomes.